Microport Scientific (853.HK) - The Subsidiaries Would Be a Better Investment
We analyzed the centralized procurement and other concerns on MicroPort. Due to its development mode, the subsidiaries are more attractive and...
529 Views
MicroPort NeuroTech IPO: Impressive Product Portfolio Offsets Profitability Concerns
Although Microport's margins have come under pressure, the company has an impressive product portfolio with a majority of them having strong...
696 Views
Pre-IPO HeMo Bioengineering - Insights on Industry, Business and Concerns
We analyzed the industry characteristics, the business and competitive landscape of HeMo. The centralized procurement, commercialization...
461 Views
Aequitas 2021 IPOs and Placements Performance Review - Busiest Year on Record
2021 marked our sixth year of Asia ECM coverage. Most markets were in top gear on the ECM front and we ended the year covering the highest number...
632 Views
Shanghai HeartCare Medcl(6609 HK): Comprehensive Stroke Produce Portfolio Comes with a Pinch of Salt
Comprehensive and innovative product portfolio addressing large patient pool is the key positive for the company. However, ongoing patent...
522 Views